AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
ProQR Therapeutics N.V. Ordinary Shares
XNAS · usd
SIC 8731 · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
FIGI BBG006N8B849
1.29▼ 0.04 (-3.01%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
1.33
Day's Range
1.24 – 1.36
52-Week Range
1.24 – 3.00
Volume
1.8M
Avg Volume
803.9K
Share Statistics
Shares Outstanding
Employees
187
Exchange
XNAS
Listed
2014-09-18
Share count as of December 31, 2025

ProQR Therapeutics N.V. Ordinary Shares (PRQR) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about ProQR Therapeutics N.V. Ordinary Shares (PRQR)
What is ProQR Therapeutics N.V. Ordinary Shares's Market Cap?
ProQR Therapeutics N.V. Ordinary Shares's Market Cap is $135.9M, based on as-reported figures from SEC (XBRL) filings.
What is ProQR Therapeutics N.V. Ordinary Shares's Enterprise Value?
ProQR Therapeutics N.V. Ordinary Shares's Enterprise Value is $33.2M, based on as-reported figures from SEC (XBRL) filings.
What is ProQR Therapeutics N.V. Ordinary Shares's Price / Sales?
ProQR Therapeutics N.V. Ordinary Shares's Price / Sales is 7.3×, based on as-reported figures from SEC (XBRL) filings.
What is ProQR Therapeutics N.V. Ordinary Shares's EV / Revenue?
ProQR Therapeutics N.V. Ordinary Shares's EV / Revenue is 1.8×, based on as-reported figures from SEC (XBRL) filings.
What is ProQR Therapeutics N.V. Ordinary Shares's EV / EBITDA?
ProQR Therapeutics N.V. Ordinary Shares's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is ProQR Therapeutics N.V. Ordinary Shares's Revenue (TTM)?
ProQR Therapeutics N.V. Ordinary Shares's Revenue (TTM) is $18.7M, based on as-reported figures from SEC (XBRL) filings.
What is ProQR Therapeutics N.V. Ordinary Shares's Net Income (TTM)?
ProQR Therapeutics N.V. Ordinary Shares's Net Income (TTM) is -$49.5M, based on as-reported figures from SEC (XBRL) filings.
What is ProQR Therapeutics N.V. Ordinary Shares's EBITDA?
ProQR Therapeutics N.V. Ordinary Shares's EBITDA is -$47.8M, based on as-reported figures from SEC (XBRL) filings.
What is ProQR Therapeutics N.V. Ordinary Shares's Diluted EPS (TTM)?
ProQR Therapeutics N.V. Ordinary Shares's Diluted EPS (TTM) is -0.47, based on as-reported figures from SEC (XBRL) filings.
What is ProQR Therapeutics N.V. Ordinary Shares's EBITDA Margin?
ProQR Therapeutics N.V. Ordinary Shares's EBITDA Margin is -256.1%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · PRQRAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of EUR, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
Revenue
Other income
Research and development costs
General and administrative costs
Total operating costs
Operating result
Financial income
Financial expense
Gain on disposal of associate—
Gain on disposal of subsidiary—
Results related to derecognition of financial liabilities—
Results related to financial liabilities measured at FVTPL
Result before corporate income taxes
Corporate income taxes
Result for the year
Items that will never be reclassified to profit or loss
Fair value loss on investment in financial asset designated as at FVTOCI—
Items that are or may be reclassified to profit or loss
Foreign operations - foreign currency translation differences
Total comprehensive loss
Result attributable to
Owners of the Company
Non-controlling interests—
Result for the year
Total comprehensive loss attributable to
Owners of the Company
Non-controlling interests—
Total comprehensive loss
Earnings per share attributable to owners of the Company (Euro per share)
Basic loss per share
Diluted loss per share